Kodiak Sciences Stock Soars to New 52-Week High

Shares of the biotech company reach new milestone as analysts raise price targets.

Apr. 13, 2026 at 3:38pm

Got story updates? Submit your updates here. ›

An extreme close-up of a highly detailed, industrial-looking medical device or laboratory equipment, capturing the intricate mechanics and advanced technology behind Kodiak Sciences' innovative retinal therapies.Kodiak Sciences' cutting-edge research and development efforts are driving its stock to new heights as investors bet on the company's potential to revolutionize treatments for debilitating eye diseases.Palo Alto Today

Shares of Kodiak Sciences (NASDAQ:KOD) hit a new 52-week high on Monday, trading as high as $46.67 before closing at $44.63. The biopharmaceutical company, which focuses on developing novel therapies for retinal diseases, has seen its stock price surge in recent months as analysts have raised their price targets.

Why it matters

Kodiak Sciences' stock performance is a positive sign for the company as it continues to advance its pipeline of experimental eye treatments. The new 52-week high reflects growing investor confidence in the company's prospects, particularly around its lead candidate KSI-301 for conditions like wet age-related macular degeneration and diabetic macular edema.

The details

Several research analysts have recently issued upbeat reports on Kodiak Sciences, with UBS Group lifting its price target from $50 to $80 and HC Wainwright raising its target from $38 to $58. The company's stock has more than doubled in value over the past year as it makes progress in its clinical trials.

  • Kodiak Sciences' stock hit a new 52-week high of $46.67 during intraday trading on Monday, April 13, 2026.
  • The company's shares closed at $44.63 on April 13, 2026.

The players

Kodiak Sciences Inc.

A clinical-stage biopharmaceutical company focused on developing novel therapies for retinal diseases, including wet age-related macular degeneration and diabetic macular edema.

UBS Group

A global financial services firm that recently raised its price target on Kodiak Sciences' stock from $50 to $80.

HC Wainwright

An investment bank that increased its price target on Kodiak Sciences from $38 to $58.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

The takeaway

Kodiak Sciences' new 52-week high reflects growing investor optimism around the company's pipeline of experimental eye treatments, particularly its lead candidate KSI-301. The positive analyst sentiment and stock performance suggest the biotech firm is making meaningful progress in its clinical development efforts.